🇺🇸 FDA
Patent

US 11472861

Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

granted A61KA61K38/179A61K38/1866

Quick answer

US patent 11472861 (Methods for producing aflibercept in chemically defined media having reduced aflibercept variants) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K38/179, A61K38/1866, A61P, A61P17/06